Karunya Srinivasan

Karunya Srinivasan has a wealth of experience in the field of preclinical and clinical biomarker development. Karunya began their career in 2003 as a Research Associate at Harvard Medical School's MassGeneral Institute for Neurodegenerative Disease (MIND). Karunya then moved to Rensselaer Polytechnic Institute in 1999, where they were a Masters Graduate Student and Research Assistant, studying sequence alignment and homology-modeling, as well as site-directed mutagenesis, PCR, cloning, and transformation. From 2005 to 2012, they worked as a Research Associate at Galenea Corp, where they analyzed a mouse model for schizophrenia and validated selected targets. In 2012, they joined Momenta Pharmaceuticals as a Scientist, where they developed assays for discrimination of novel Immuno-Oncology designs from FDA approved antibodies. In 2018, they began working at Marengo Therapeutics as a Principal Scientist, Preclinical & Clinical Biomarker Lead, where they are responsible for managing a broad range of preclinical activities and leading the development and validation of clinical biomarker assays for implementation in trials.

Karunya Srinivasan's education history includes a PhD in Biological Engineering from the Massachusetts Institute of Technology (2007-2012), a Master of Science in Biology from Rensselaer Polytechnic Institute (2001-2003), a Master of Science in Chemical Engineering from Rensselaer Polytechnic Institute (1999-2001), and a B.Tech in Chemical Engineering from Osmania University (1995-1999).